EP0138297A1 - Teilchensuspensionen für die Immuno-Agglutination - Google Patents
Teilchensuspensionen für die Immuno-Agglutination Download PDFInfo
- Publication number
- EP0138297A1 EP0138297A1 EP84304370A EP84304370A EP0138297A1 EP 0138297 A1 EP0138297 A1 EP 0138297A1 EP 84304370 A EP84304370 A EP 84304370A EP 84304370 A EP84304370 A EP 84304370A EP 0138297 A1 EP0138297 A1 EP 0138297A1
- Authority
- EP
- European Patent Office
- Prior art keywords
- avidin
- particles
- antibody
- core
- biotin
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/543—Immunoassay; Biospecific binding assay; Materials therefor with an insoluble carrier for immobilising immunochemicals
- G01N33/54313—Immunoassay; Biospecific binding assay; Materials therefor with an insoluble carrier for immobilising immunochemicals the carrier being characterised by its particulate form
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10S436/00—Chemistry: analytical and immunological testing
- Y10S436/823—Immunogenic carrier or carrier per se
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10T—TECHNICAL SUBJECTS COVERED BY FORMER US CLASSIFICATION
- Y10T436/00—Chemistry: analytical and immunological testing
- Y10T436/25—Chemistry: analytical and immunological testing including sample preparation
- Y10T436/25875—Gaseous sample or with change of physical state
Definitions
- the present invention relates to tests wnicn employ antibodies to detect the presence of particular antigenic substances and more particularly to improved suspensions of antibody molecules bound to solid support particles which agglutinate in the presence of the particular antigen to which the antibody is reactive.
- Antibodies are large proteinaceous molecules that are produced by animals in response to the presence of a foreign substance for the purpose of neutralizing that substance.
- An antibody molecule may be highly specific, recognizing only a certain site of a particular molecule which is the antigen to that antibody. Because of their high specificities, antibodies are very useful in ascertaining the presence or absence of various antigenic substances, and a number of test procedures, such as radioimmunoassays, have been developed to take advantage of the specificity of the antibodies.
- test procedures such as radioimmunoassays, have been developed to take advantage of the specificity of the antibodies.
- monoclonal antibodies have been developed, providing a practical method for assuring that an antibody fraction contains only a single type of antibody molecule. Monoclonal antibodies may be substituted for conventional antibody fractions in most diagnostic tests, providing greater accuracy and reliability than tests which utilize conventional antibody fractions.
- agglutination test One particular type of test which has been developed that is particularly useful for detecting the presence of large antigens having multiple antibody- recognition sites (antigenic determinants), is an agglutination test.
- Antibody molecules are bound to minute particles formed of a polymer and the particle-bound antibody is suspended in a liquid medium. In the presence of the antigen, the particle-bound antibody attaches to the recognition sites on the antigen. If antibody molecules on more than one particle attach to the same antigen molecule, the particles become cross-linked, and as multiple particles cross-link, they agglutinate and precipitate from the solution. Agglutination and precipitation of the suspended particles is readily observable by the naked eye, providing a very simple and very certain test that a particular antigen is present.
- Another method of binding antibodies to latex particles is through adsorption of antibodies to the surface of latex particles, as is described in Carel J. Van Oss and J. M. Singer; "The Binding of Immune Globulins and Other Proteins by Polystyrene Latex Particles", J. Reticuloendothelial Soc. (1966) 3, pp. 29-40.
- the success of this procedure depends to a great extent on the exact lot of the latex, different lots having vastly different adsorptive properties and stabilities. Because of the unpredictability of results, this procedure is used largely for larger antibody molecules, such as IgM.
- latex particles having bound antibody which can be more reproducibly manufactured, irrespective of the type of antibody and irrespective of the adsorptive properties of the particular lot of latex particles. It would be further desirable to control the number of antibody molecules binding to the particles to assure that premature agglutination will not occur due to the particles having excessive bound antibody molecules and yet assure that there are sufficient bound antibody molecules to agglutinate the particles rapidly in the presence of the antigen.
- the invention provides a diagnostic composition
- a diagnostic composition comprising a suspension of carboxylate derivatized latex particles bound to antibody molecules through avidin-biotin bridges.
- the latex particles having multiple free carboxyl groups on their surfaces, are bound to avidin using a carbodiimide intermediate.
- Biotin is covalently bound to the antibody.
- a mixture of biotin and biotinylated antibody in a predetermined molar ratio are reacted with the latex-bound avidin, linking antibody moieties to a selected portion of the avidin binding sites.
- the number of antibody molecules attached through avidin-biotin bridges to the latex is controlled to assure that the particles remain in suspension until they cross-link and agglutinate in the presence of an antigen to the antibody.
- diagnostic particles are provided in which antibodies are attached to carboxylate-derivatized latex particles through avidin-biotin bridges.
- the diagnostic particles comprise carboxylate derivitized polymeric core particles, avidin moieties linked through amide bonds to the core particles, biotin moieties complexed to the avidin moities and antibody (immunoglobulin) molecules linked to the biotin moieties through amide bonds.
- the diagnostic particles are suspended in a liquid medium to form a latex composition that is useful for diagnosing the presence of an antigen to which the bound antibody is specific.
- the diagnostic particles suspended in the liquid medium agglutinate by cross-linking through antigen molecules that have multiple antigenic determinants recognized by the antibody, and the cross-linked diagnostic particles precipitate from the liquid medium.
- carboxylate derivatized latex core particles are attached to avidin through an amide bond formed between the surface carboxyl groups of the polymeric core particle and primary amino groups on the avidin.
- An antibody of interest is attached to biotin through an amide bond formed by the carboxyl group of biotinic acid and an amine group of the antibody.
- Avidin has a very strong affinity for biotin, and the antibody-bound biotin moiety readily complexes to an avidin moiety linked to the core particle. To assure that the diagnostic particles will be stable as a latex suspension until agglutination testing, the number of antibody moieties linked to each core particle is controlled.
- biotinylated antibody To prevent excessive biotinylated antibody from complexing to the avidin moities linked to the core particles, a mixture of free biotinic acid.and biotinylated antibody of a predetermined molar ratio is reacted with the core particle-bound avidin so that biotinic acid occupies a portion of the binding sites on the avidin which might otherwise be occupied by the biotinylated antibody.
- latex herein is used broadly to include stable dispersions of particles of polymeric material. Suitable latexes include suspensions of minute polystyrene and polyacrylamide particles. To provide that a stable suspension of the diagnostic particle can be formed which will precipitate within a reasonable time upon exposure to the antigen, the starting polymeric core particles should be between about 0.2 and about 1.0 micron in diameter.
- the polymeric core particles are carboxylate derivatized to provide exposed carboxyl groups at their surfaces for attachment of avidin.
- Polyacrylamide particles may be derivatized by the method of John K. Inman, "Covalent Linkage of Functional Groups, Ligands, and Proteins to Polyacrylamide Beads", in Methods in Enzymology, Vol XXXIV, (ed. William B. Jakoby and Meir Wilchek, Academic Press, N.Y., 1974) pp. 30-58.
- Suitable carboxylate-derivatized latex particles are commercially available; for example, carboxylate-latex sold by Polysciences. It is found that particles carboxylated to between 0.1 and about 0.5 milliequivalents per gram are most suitable.
- Biotin hexahydro-2-oxo-lH-thieno [3,4] imidazole-4-pentanoic acid
- Biotin is a growth factor present in very minute amounts of every living cell and is found mainly bound to proteins or polypeptides.
- Avidin is a glycoprotein containing four essentially identical peptide subunits, each having an attached carbohydrate moiety. Each subunit of avidin has a single biotin binding site. The combined molecular weight of the subunits is about 66,000.
- Avidin is most commonly isolated from raw egg whites but is probably found in the genital tract of all animals. Avidin is also produced by certain bacteria, such as Streptomyces avidinii, and avidin used herein is to be understood to refer to animal avidin as well as bacterial avidin, such as streptavidin. The high affinity of avidin for biotin has been demonstrated by the ability of large amounts of avidin to produce biotin deficiency in rats and chicks.
- the core particles have a greater number of surface carboxyl groups than are to be eventually linked to antibody molecules
- avidin is reacted with the core particles in amounts less than the stoichiometric concentration which would link to all core surface carboxyl groups. It is not preferred, however, to control the number of biotinylated antibody molecules that are subsequently linked to the cores by limiting the number of avidin molecules that are bound to the cores to the minimum that would be required to complex stoichiometrically to the desired number of biotinylated antibody molecules.
- the antibody is selected according to the antigen to be detected.
- Any of the known types of immunoglobulins can be linked to latex core particles by the method of the present invention, including IgG, IgA and IgM.
- a general requirement is that the antibody be specific for an antigen having at least two antigenic determinants so that the antigen can bind to antibodies on different diagnostic particles and thereby cross-link the particles.
- Many large antigens of interest such as the group carbohydrate antigen of Group A Streptococcus, have multiple, substantially identical, antigenic determinants.
- the particular antigen does not have duplicate antigenic determinants, it may have spaced-apart distinct antigenic determinants, in which case a mixture of two or more antibodies, each reactive with one of the determinants, might be linked to the latex core particles to allow cross-linking between diagnostic particles to take place through the unique antigenic determinants.
- monoclonal antibodies be used to detect antigens.
- Monoclonal antibodies consisting of identical antibody molecules, are much more specific than conventionally obtained antibody fractions and provide for much greater reproducability between lots of diagnostic particles.
- “Monoclonal antibodies” is used herein to refer to antibodies generated by hybridomas, as well as antibodies produced by other cell immortalization techniques, e.g., by infection with certain viruses.
- the invention is intended to encompass diagnostic particles incorporating conventional antibody fractions, particularly to detect antigens for which no monoclonal antibody is presently available.
- the formation of the amide bond between the carboxyl groups on the latex core particles and an amine group of the avidin is preferably facilitated through an intermediate formed by reaction of a carbodiimide, such as l-ethyl-3-(3-dimethylaminopropyl) carbodiimide, with the carboxyl groups on the latex particles.
- a carbodiimide such as l-ethyl-3-(3-dimethylaminopropyl) carbodiimide
- a preferred method of forming the amide bond between the carboxyl group of biotin and an amino group of the antibody molecule is by initially forming an ester between an N-hydroxy imide, such as N-hydroxy-succinimide and biotin and then reacting the N-hydroxy imide-biotin with the immunoglobulin, whereupon an amino group of the immunoglobulin replaces the N-hydroxyimide linked to the carbonyl.
- This reaction is carried out at slightly alkaline conditions, preferably at a pH of between about 7.5 and about 9.0.
- unbound surface carboxyl groups remain on the latex core particles.
- These unbound carboxyl groups are preferably neutralized, e.g., with an amine, such as ethanol amine.
- diagnostic particles have greater stability if, subsequent to neutralization, non-immunogenic proteinaceous material, such as bovine serum albumin (BSA), is adsorbed onto the surfaces of the avidin-bound latex core particle.
- non-immunogenic proteinaceous material such as bovine serum albumin (BSA)
- Control of the amount of antibody on the surface of the diagnostic particle which is accomplished by mixing free biotinic acid with biotinylated antibody so that they compete for the excess avidin binding sites, is considered an important aspect of the invention. Too few antibody molecules may not afford agglutination at a suitable rate, whereas too many antibody molecules may result in premature precipitation. Generally, it is preferred that between 2 x1 0 11 and about 2x10 12 antibody molecules be bound per cm of estimated surface area of the latex core particles, although this may vary somewhat depending upon whether the antibody is small, e.g., IgG, or large, e.g., IgM. The molar ratio of biotinic acid to biotinylated antibody ratio is dependent on the number of avidin binding sites.
- the liquid medium in which the diagnostic particles are suspended is generally aqueous as is consistent with the natural environment of antibody molecules.
- a slightly basic pH e.g., between about 7.5 and about 8.5, contributes to stability of the diagnostic particles.
- Antimicrobial agents, such as NaN 3 may also be added to the medium.
- latex suspensions for use in agglutination tests contain between about 5 and about 10 gm. of particles per liter of suspension.
- Antibodies are bound to biotin as follows:
- biotinylated antibodies formed above, is attached to the avidin-latex particles.
- 1.0 ml. of avidin latex is pelleted and the supernatant removed.
- the pellet is taken up in 1.0 ml of biotinylated antibody containing 5 ⁇ l of 10 M biotinic acid, and the mixture is stirred for 1 hour at 22°C to react the biotin and biotinylated antibody.
- a second 5 ⁇ l aliquot of 10" M biotinic acid is added to block potentially unoccupied biotin binding sites on the avidin moieties.
- the diagnostic particles are centrifuged, washed and suspended at 0.6% solids in 0.1 M glycine-saline buffer, pH 8.2 containing 0.2% NaN 3 , 0.2% BSA and 0.05% Tween-20.
- Suspensions of diagnostic particles prepared according to the present invention are stable if stored under refrigeration for periods of several months.
- the diagnostic particles are extremely sensitive, and using microtechniques, the suspensions can be used to detect as little as nanogram quantities of antigen.
- the invention provides for attachment of all types of immunoglobulins, including IgM.
- the amount of antibody attached to the latex is not dependent upon the adsorption characteristics of a particular lot of latex.
- the degree of carboxylation is preferably within a certain range, the amount of antibody attached is determined independently of the precise degree of carboxylation of the core particles, i.e., by the less than stoichiometric amount of avidin bound to the carboxyl groups and then by the selected molar ratios of biotinic acid and biotinylated antibody.
- reproducability of manufacture is significantly enhanced relative to prior latex particle to antibody linking procedures, particularly with respect to IgM which previously had to be bound to the latex by the highly variable adsorption technique.
- the amount of antibody bound to the particles could be made through control of the number of avidin molecules bound to the latex core particles followed by saturation of the biotin binding sites with biotinylated antibody molecules.
- the diagnostic particle suspensions generally require that the antigen be large, having at least two antigenic determinant sites, it is also contemplated that a small antigenically active molecule or hapten could agglutinate the particles if the particles were suspended in a liquid medium that contained a chemical which would link two or more of the hapten molecules.
Landscapes
- Health & Medical Sciences (AREA)
- Immunology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Molecular Biology (AREA)
- Biomedical Technology (AREA)
- Chemical & Material Sciences (AREA)
- Hematology (AREA)
- Urology & Nephrology (AREA)
- Biotechnology (AREA)
- Microbiology (AREA)
- Cell Biology (AREA)
- Food Science & Technology (AREA)
- Medicinal Chemistry (AREA)
- Physics & Mathematics (AREA)
- Analytical Chemistry (AREA)
- Biochemistry (AREA)
- General Health & Medical Sciences (AREA)
- General Physics & Mathematics (AREA)
- Pathology (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US537737 | 1983-09-30 | ||
US06/537,737 US4582810A (en) | 1983-09-30 | 1983-09-30 | Immuno-agglutination particle suspensions |
Publications (2)
Publication Number | Publication Date |
---|---|
EP0138297A1 true EP0138297A1 (de) | 1985-04-24 |
EP0138297B1 EP0138297B1 (de) | 1989-08-16 |
Family
ID=24143893
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EP84304370A Expired EP0138297B1 (de) | 1983-09-30 | 1984-06-27 | Teilchensuspensionen für die Immuno-Agglutination |
Country Status (9)
Country | Link |
---|---|
US (1) | US4582810A (de) |
EP (1) | EP0138297B1 (de) |
JP (1) | JPS6080766A (de) |
AU (1) | AU563639B2 (de) |
CA (1) | CA1222450A (de) |
DE (1) | DE3479443D1 (de) |
DK (1) | DK159176C (de) |
FI (1) | FI78788C (de) |
MY (1) | MY100973A (de) |
Cited By (15)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0214392A1 (de) * | 1985-07-02 | 1987-03-18 | Omni Medical Limited | Medizinisches Gerät, insbesondere Filter, Kanüle, Katheter oder Implantat |
FR2601455A1 (fr) * | 1986-07-11 | 1988-01-15 | Stallergenes Lab | Nouveaux reactifs biologiques en phase solide et leur procede d'obtention |
EP0349988A2 (de) * | 1988-07-05 | 1990-01-10 | Roche Diagnostics GmbH | Verfahren zur Bestimmung einer spezifisch bindefähigen Substanz |
EP0356964A2 (de) * | 1988-08-29 | 1990-03-07 | Roche Diagnostics GmbH | Verfahren zur Bestimmung einer spezifisch bindefähigen Substanz |
EP0365449A1 (de) * | 1988-10-20 | 1990-04-25 | Immunotech S.A. | Immunoadsorbens mit geringer Freisetzungsrate und Verfahren zu seiner Herstellung |
EP0397113A2 (de) * | 1989-05-09 | 1990-11-14 | Roche Diagnostics GmbH | Verfahren zum Nachweis spezifisch bindefähiger Substanzen in Körperflüssigkeiten |
EP0416730A2 (de) * | 1989-09-08 | 1991-03-13 | Hewlett-Packard Company | Herstellung einer Festphase, geeignet für spezifische Bindung chemischer Substanzen |
EP0423938A1 (de) * | 1989-09-29 | 1991-04-24 | Rohm And Haas Company | Ligand enthaltendes Medium für chromatographische Trennung, Verfahren zur dessen Herstellung und dessen Verwendung zur Isolierung von synthetischen oder natürlichen Molekülen von einer Fluidmischung |
EP0439222A2 (de) * | 1990-01-26 | 1991-07-31 | Johnson & Johnson Clinical Diagnostics, Inc. | Wasserunlösbares Reagenz, Nukleinsäure-Sonde, Testsatz und Verfahren zur Diagnose und Isolierung |
US5061237A (en) * | 1985-07-02 | 1991-10-29 | Cytomed Medizintechnik Gmbh | Method of purifying whole blood |
EP0462670A1 (de) * | 1990-06-18 | 1991-12-27 | Johnson & Johnson Clinical Diagnostics, Inc. | Verwendung von 1-(1-Pyrrolidinylcarbonyl)pyridiniumsalzen zur Ankoppelung von Verbindungen an carboxylierte Teilchen und Reagenziensatz diese beinhaltend |
EP0700933A1 (de) * | 1994-09-09 | 1996-03-13 | Societe Prolabo | Mikrokugel-Biotinlatex, Verfahren zur Herstellung von solchen Mikrokugeln und Verwendung als biologische Nachweismittel |
US6235488B1 (en) | 1988-09-29 | 2001-05-22 | Agilent Technologies, Inc. | Surface preparation for chemical-specific binding |
US7194308B2 (en) | 2003-11-12 | 2007-03-20 | Cardiac Pacemakers, Inc. | System and method for monitoring or reporting battery status of implantable medical device |
WO2020099533A1 (en) * | 2018-11-16 | 2020-05-22 | F. Hoffmann-La Roche Ag | Streptavidin-coated solid phases with a member of a binding pair |
Families Citing this family (44)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AU582341B2 (en) * | 1984-01-27 | 1989-03-23 | Molecular Biosystems, Inc. | Assay for immobilized reporter groups |
US4618576A (en) * | 1984-02-27 | 1986-10-21 | Becton Dickinson And Company | Diagnostic test for Streptococcus A |
US4920061A (en) * | 1984-03-02 | 1990-04-24 | The University Of Texas System | Biological magnetic colloids |
FR2571498B1 (fr) * | 1984-10-04 | 1988-04-08 | Immunotech Sa | Procede de separation de cellules utilisant des anticorps et des billes de faible densite |
US5246829A (en) * | 1984-10-04 | 1993-09-21 | Immunotech | Products for separation applicable to cells in the immunopurification field |
WO1987004794A1 (en) * | 1986-02-06 | 1987-08-13 | Microbiological Associates, Inc. | Latex agglutination using avidin/biotin system |
DE3637253A1 (de) * | 1986-11-03 | 1988-05-05 | Behringwerke Ag | Latex-agglutinations-verfahren zum nachweis von anti-streptokokken-desoxyribonuclease b |
US4791067A (en) * | 1987-06-25 | 1988-12-13 | Fisher Scientific Co. | Agglutination immunoassay for hapten involving monoclonal antibody of IgA class reagent |
US5132242A (en) * | 1987-07-15 | 1992-07-21 | Cheung Sau W | Fluorescent microspheres and methods of using them |
JPH07107537B2 (ja) * | 1987-08-03 | 1995-11-15 | イーストマン コダック カンパニー | アビジン−及びビオチン−固定試薬,分析要素並びにその使用法 |
CA1305664C (en) * | 1987-08-06 | 1992-07-28 | Stephen James Lovell | System and process for a visible assay for analyte |
US4859612A (en) * | 1987-10-07 | 1989-08-22 | Hygeia Sciences, Inc. | Metal sol capture immunoassay procedure, kit for use therewith and captured metal containing composite |
DK641487A (da) | 1987-12-07 | 1989-06-08 | Gluetech Aps | Fremgangsmaade til modificering af polymeroverflader |
US4870007A (en) * | 1987-12-18 | 1989-09-26 | Eastman Kodak Company | Immobilized biotinylated receptor in test device, kit and method for determining a ligand |
CA1312277C (en) * | 1987-12-18 | 1993-01-05 | Richard C. Sutton | Avidin- and biotin-immobilized reagents, analytical elements and methods of use |
US4914040A (en) * | 1988-03-03 | 1990-04-03 | Boehringer Mannheim Gmbh | Reagent and method for determination of a polyvalent substance using an immunoaggregate |
US4952519A (en) * | 1988-05-02 | 1990-08-28 | E. I. Du Pont De Nemours And Company | Protein immobilization with poly(ethyleneimine) derivatized with a hydroprobic group |
IE64286B1 (en) * | 1988-05-25 | 1995-07-26 | Boehringer Mannheim Gmbh | Process for the determination of an immunologically detectable substance and a suitable vessel therefor |
US5362624A (en) * | 1988-05-25 | 1994-11-08 | Boehringer Mannheim Gmbh | Process for the determination of an immunologically detectable substance and a suitable reaction vessel therefor |
US5389523A (en) * | 1988-05-31 | 1995-02-14 | The United States Of Americas, As Represented By The Secretary Of Commerce | Liposome immunoanalysis by flow injection assay |
ATE131617T1 (de) | 1988-10-17 | 1995-12-15 | Molecular Devices Corp | Haptenderivatisierte aufnahmemembran und diagnostische tests, die eine solche membran verwenden |
US5888728A (en) | 1988-10-17 | 1999-03-30 | Molecular Devices Corporation | Hapten derivatized capture membrane and diagnostic assays using such membrane |
US5026785A (en) * | 1989-05-12 | 1991-06-25 | The United States Of America As Represented By The Department Of Health And Human Services | Avidin and streptavidin modified water-soluble polymers such as polyacrylamide, and the use thereof in the construction of soluble multivalent macromolecular conjugates |
US5252466A (en) * | 1989-05-19 | 1993-10-12 | Biotechnology Research And Development Corporation | Fusion proteins having a site for in vivo post-translation modification and methods of making and purifying them |
US5252743A (en) * | 1989-11-13 | 1993-10-12 | Affymax Technologies N.V. | Spatially-addressable immobilization of anti-ligands on surfaces |
US5180828A (en) * | 1990-02-09 | 1993-01-19 | Molecular Devices Corporation | Chromophoric reagents for incorporation of biotin or other haptens into macromolecules |
US6274325B1 (en) * | 1990-06-25 | 2001-08-14 | Boehringer Mannheim Gmbh | Method for carrying out a homogeneous-immunoassay based on agglutination |
US5556748A (en) * | 1991-07-30 | 1996-09-17 | Xenopore Corporation | Methods of sandwich hybridization for the quantitative analysis of oligonucleotides |
DE4140142A1 (de) * | 1991-12-05 | 1993-06-09 | Boehringer Mannheim Gmbh, 6800 Mannheim, De | Multivalentes dextranreagenz zum einsatz in praezipitationstests |
WO1994015216A1 (en) * | 1992-12-23 | 1994-07-07 | Niyazmatov Agzamdzhan Akhtamov | Process for obtaining a diagnostic reagent for detecting antigens and antibodies of infectious and other illnesses |
AU687033B2 (en) * | 1993-09-13 | 1998-02-19 | Ciba Corning Diagnostics Corp. | Undercoating of solid phase surfaces and direct coating method |
US5747352A (en) * | 1994-05-23 | 1998-05-05 | Beckman Instruments, Inc. | Reagents and methods for the rapid and quantitative assay of pharmacological agents |
US5981296A (en) * | 1997-02-18 | 1999-11-09 | Dade Behring Inc. | Stabilization of particle reagents |
DE60137792D1 (de) * | 2000-12-11 | 2009-04-09 | Mitsubishi Kagaku Iatron Inc | Immunologisches verfahren |
ATE470859T1 (de) | 2001-09-06 | 2010-06-15 | Straus Holdings Inc | Schneller und empfindlicher nachweis von molekülen |
US7163998B2 (en) * | 2003-09-09 | 2007-01-16 | Eastman Kodak Company | Stabilized polymer beads and method of preparation |
WO2005062048A1 (de) | 2003-12-01 | 2005-07-07 | Dade Behring Marburg Gmbh | Homogenes nachweisverfahren |
GB2420976B (en) * | 2004-11-19 | 2006-12-20 | Zvi Finkelstein | Therapeutic implant |
US9057046B2 (en) * | 2005-09-26 | 2015-06-16 | Rapid Micro Biosystems, Inc. | Cassette containing growth medium |
US10384203B2 (en) | 2008-09-24 | 2019-08-20 | First Light Biosciences, Inc. | Kits and devices for detecting analytes |
CN104185677B (zh) | 2011-11-07 | 2016-03-02 | 快速微型生物***公司 | 用于无菌性测试的盒 |
CA3171698A1 (en) | 2012-04-16 | 2013-10-24 | Rapid Micro Biosystems, Inc. | Cell culturing device |
EP3274724A1 (de) | 2015-03-25 | 2018-01-31 | Alexion Pharmaceuticals, Inc. | Verfahren zur messung der proteaseaktivität von faktor d des alternativen komplementweges |
TR201904903T4 (tr) | 2015-03-25 | 2019-05-21 | Alexion Pharma Inc | Alternatif tamamlama yolağının C3 ve C5 konvertazının proteaz aktivitesinin ölçülmesine yönelik bir yöntem. |
Citations (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE1598859A1 (de) * | 1965-04-15 | 1972-03-16 | Organon Nv | Reagentien fuer immunochemische Bestimmungen |
DE2203377A1 (de) * | 1971-02-01 | 1972-08-17 | Hoffmann La Roche | Immunologisches Diagnose-Reagenz |
DE2529937A1 (de) * | 1974-07-08 | 1976-01-29 | Takeda Chemical Industries Ltd | Serologisches reagenz und verfahren zu seiner herstellung |
DE2533701A1 (de) * | 1974-08-01 | 1976-02-12 | American Cyanamid Co | Immunologische diagnoseprodukte |
EP0008682A1 (de) * | 1978-08-02 | 1980-03-19 | F. HOFFMANN-LA ROCHE & CO. Aktiengesellschaft | Mit einem Proteinmaterial beschichteter Latex, Verfahren zur Herstellung dieses Latex, immunologisches Reagenz enthaltend diesen Latex, Verfahren zur Herstellung dieses Reagenzes, Verwendung dieses Reagenzes, Bestimmungsverfahren unter Verwendung dieses Reagenzes und Reagenziengarnitur enthaltend dieses Reagenz |
EP0070527A1 (de) * | 1981-07-17 | 1983-01-26 | Toray Industries, Inc. | Verfahren zum Untersuchen von biologisch aktiven Substanzen und Markierungsmittel hierfür |
EP0100955A2 (de) * | 1982-07-26 | 1984-02-22 | Amf Incorporated | Monoklonale Immunoglobulin-M-Antikörper und Verfahren zu deren Herstellung |
Family Cites Families (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CA1083508A (fr) * | 1975-11-13 | 1980-08-12 | Jacques Grange | Supports porteurs de chaines laterales, procedes d'obtention de ces supports, procedes de fixation de composes organiques comportant un residu glucidique sur lesdits supports, produits et reactifs resultant de ladite fixation chimique |
JPS5510590A (en) * | 1978-05-04 | 1980-01-25 | Wellcome Found | Enzyme immunity quantity analysis |
US4228237A (en) * | 1978-09-21 | 1980-10-14 | Calbiochem-Behring Corp. | Methods for the detection and determination of ligands |
US4276206A (en) * | 1979-01-18 | 1981-06-30 | Scripps Clinic & Research Foundation | Immunochemical conjugates: method and composition |
US4220565A (en) * | 1979-01-18 | 1980-09-02 | Scripps Clinic & Research Foundation | Immunochemical conjugates: method and composition |
US4282287A (en) * | 1980-01-24 | 1981-08-04 | Giese Roger W | Biochemical avidin-biotin multiple-layer system |
JPS56115727A (en) * | 1980-02-19 | 1981-09-11 | Kuraray Co Ltd | Carrier for immobilizing physiologically active substance |
US4434150A (en) * | 1981-10-19 | 1984-02-28 | Ortho Diagnostic Systems, Inc. | Immunological reagents employing polymeric backbone possessing reactive functional groups |
-
1983
- 1983-09-30 US US06/537,737 patent/US4582810A/en not_active Expired - Fee Related
-
1984
- 1984-05-08 CA CA000453773A patent/CA1222450A/en not_active Expired
- 1984-05-21 AU AU28433/84A patent/AU563639B2/en not_active Ceased
- 1984-06-27 DE DE8484304370T patent/DE3479443D1/de not_active Expired
- 1984-06-27 EP EP84304370A patent/EP0138297B1/de not_active Expired
- 1984-07-10 JP JP59143189A patent/JPS6080766A/ja active Pending
- 1984-07-18 FI FI842889A patent/FI78788C/fi not_active IP Right Cessation
- 1984-08-15 DK DK391884A patent/DK159176C/da active
-
1987
- 1987-09-29 MY MYPI87002102A patent/MY100973A/en unknown
Patent Citations (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE1598859A1 (de) * | 1965-04-15 | 1972-03-16 | Organon Nv | Reagentien fuer immunochemische Bestimmungen |
DE2203377A1 (de) * | 1971-02-01 | 1972-08-17 | Hoffmann La Roche | Immunologisches Diagnose-Reagenz |
DE2529937A1 (de) * | 1974-07-08 | 1976-01-29 | Takeda Chemical Industries Ltd | Serologisches reagenz und verfahren zu seiner herstellung |
DE2533701A1 (de) * | 1974-08-01 | 1976-02-12 | American Cyanamid Co | Immunologische diagnoseprodukte |
EP0008682A1 (de) * | 1978-08-02 | 1980-03-19 | F. HOFFMANN-LA ROCHE & CO. Aktiengesellschaft | Mit einem Proteinmaterial beschichteter Latex, Verfahren zur Herstellung dieses Latex, immunologisches Reagenz enthaltend diesen Latex, Verfahren zur Herstellung dieses Reagenzes, Verwendung dieses Reagenzes, Bestimmungsverfahren unter Verwendung dieses Reagenzes und Reagenziengarnitur enthaltend dieses Reagenz |
EP0070527A1 (de) * | 1981-07-17 | 1983-01-26 | Toray Industries, Inc. | Verfahren zum Untersuchen von biologisch aktiven Substanzen und Markierungsmittel hierfür |
EP0100955A2 (de) * | 1982-07-26 | 1984-02-22 | Amf Incorporated | Monoklonale Immunoglobulin-M-Antikörper und Verfahren zu deren Herstellung |
Cited By (26)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5061237A (en) * | 1985-07-02 | 1991-10-29 | Cytomed Medizintechnik Gmbh | Method of purifying whole blood |
EP0214392A1 (de) * | 1985-07-02 | 1987-03-18 | Omni Medical Limited | Medizinisches Gerät, insbesondere Filter, Kanüle, Katheter oder Implantat |
FR2601455A1 (fr) * | 1986-07-11 | 1988-01-15 | Stallergenes Lab | Nouveaux reactifs biologiques en phase solide et leur procede d'obtention |
US5858803A (en) * | 1988-07-05 | 1999-01-12 | Boehringer Mannheim Gmbh | Process and reagent for the determination of a specifically bindable substance |
EP0349988A2 (de) * | 1988-07-05 | 1990-01-10 | Roche Diagnostics GmbH | Verfahren zur Bestimmung einer spezifisch bindefähigen Substanz |
EP0349988A3 (en) * | 1988-07-05 | 1990-11-07 | Boehringer Mannheim Gmbh | Method to determine a specific substance capable of binding |
EP0356964A2 (de) * | 1988-08-29 | 1990-03-07 | Roche Diagnostics GmbH | Verfahren zur Bestimmung einer spezifisch bindefähigen Substanz |
US5362655A (en) * | 1988-08-29 | 1994-11-08 | Boehringer Mannheim Gmbh | Process for the determination of a specifically bindable substance |
EP0356964A3 (de) * | 1988-08-29 | 1991-01-16 | Roche Diagnostics GmbH | Verfahren zur Bestimmung einer spezifisch bindefähigen Substanz |
US6235488B1 (en) | 1988-09-29 | 2001-05-22 | Agilent Technologies, Inc. | Surface preparation for chemical-specific binding |
EP0365449A1 (de) * | 1988-10-20 | 1990-04-25 | Immunotech S.A. | Immunoadsorbens mit geringer Freisetzungsrate und Verfahren zu seiner Herstellung |
EP0397113A3 (de) * | 1989-05-09 | 1991-05-29 | Roche Diagnostics GmbH | Verfahren zum Nachweis spezifisch bindefähiger Substanzen in Körperflüssigkeiten |
EP0397113A2 (de) * | 1989-05-09 | 1990-11-14 | Roche Diagnostics GmbH | Verfahren zum Nachweis spezifisch bindefähiger Substanzen in Körperflüssigkeiten |
US5212063A (en) * | 1989-05-09 | 1993-05-18 | Boehringer Mannheim Gmbh | Ligand trap useful in immunoassays of biotin or free biotin containing samples and improved immunoassays using these ligand traps |
EP0416730A2 (de) * | 1989-09-08 | 1991-03-13 | Hewlett-Packard Company | Herstellung einer Festphase, geeignet für spezifische Bindung chemischer Substanzen |
EP0416730A3 (en) * | 1989-09-08 | 1992-07-01 | Hewlett-Packard Company | Substrate preparation for chemical-species-specific binding |
TR26082A (tr) * | 1989-09-29 | 1994-12-15 | Rohm & Haas | KROMOTOGRAFIK AYIRIM ICIN LIGAND IHTIVA EDEN ORTAM BU ORTAMI HAZIRLAMAYA MAHSUS YÖNTEM VE BU ORTAMIN BIR AKISKAN KARISIMINDAN SENTETIK VEYA DOGAL MOLEKüLLERI AYIRMAK ICIN KULLANILMASI |
EP0423938A1 (de) * | 1989-09-29 | 1991-04-24 | Rohm And Haas Company | Ligand enthaltendes Medium für chromatographische Trennung, Verfahren zur dessen Herstellung und dessen Verwendung zur Isolierung von synthetischen oder natürlichen Molekülen von einer Fluidmischung |
EP0439222A3 (en) * | 1990-01-26 | 1991-09-18 | Eastman Kodak Company | Water-insoluble reagent, nucleic acid probe, test kit and diagnostic and purification methods |
EP0439222A2 (de) * | 1990-01-26 | 1991-07-31 | Johnson & Johnson Clinical Diagnostics, Inc. | Wasserunlösbares Reagenz, Nukleinsäure-Sonde, Testsatz und Verfahren zur Diagnose und Isolierung |
EP0462670A1 (de) * | 1990-06-18 | 1991-12-27 | Johnson & Johnson Clinical Diagnostics, Inc. | Verwendung von 1-(1-Pyrrolidinylcarbonyl)pyridiniumsalzen zur Ankoppelung von Verbindungen an carboxylierte Teilchen und Reagenziensatz diese beinhaltend |
EP0700933A1 (de) * | 1994-09-09 | 1996-03-13 | Societe Prolabo | Mikrokugel-Biotinlatex, Verfahren zur Herstellung von solchen Mikrokugeln und Verwendung als biologische Nachweismittel |
FR2724461A1 (fr) * | 1994-09-09 | 1996-03-15 | Prolabo Sa | Microsphere de latex biotinylee, procede de preparation d'une telle microsphere et utilisation en tant qu'agent de detection biologique |
US5795719A (en) * | 1994-09-09 | 1998-08-18 | Societe Prolabo | Biotinylated latex microsphere, process for the preparation of such a microsphere and use as agent for biological detection |
US7194308B2 (en) | 2003-11-12 | 2007-03-20 | Cardiac Pacemakers, Inc. | System and method for monitoring or reporting battery status of implantable medical device |
WO2020099533A1 (en) * | 2018-11-16 | 2020-05-22 | F. Hoffmann-La Roche Ag | Streptavidin-coated solid phases with a member of a binding pair |
Also Published As
Publication number | Publication date |
---|---|
FI78788B (fi) | 1989-05-31 |
DK391884D0 (da) | 1984-08-15 |
CA1222450A (en) | 1987-06-02 |
JPS6080766A (ja) | 1985-05-08 |
FI842889A (fi) | 1985-03-31 |
MY100973A (en) | 1991-06-15 |
DK391884A (da) | 1985-03-31 |
FI78788C (fi) | 1989-09-11 |
US4582810A (en) | 1986-04-15 |
EP0138297B1 (de) | 1989-08-16 |
FI842889A0 (fi) | 1984-07-18 |
AU563639B2 (en) | 1987-07-16 |
DK159176B (da) | 1990-09-10 |
AU2843384A (en) | 1985-04-04 |
DK159176C (da) | 1991-03-11 |
DE3479443D1 (en) | 1989-09-21 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US4582810A (en) | Immuno-agglutination particle suspensions | |
Quash et al. | The preparation of latex particles with covalently bound polyamines, IgG and measles agglutinins and their use in visual agglutination tests | |
CA1118344A (en) | Bridging the sulphur atom of antigen, antibody or fragments to a substrate | |
EP0961934B1 (de) | Teilchen mit polyaldehyd-dextran-überzug, die verkleinerte matrixeffekte aufweisen | |
EP0064318B1 (de) | Verfahren und Ausrüstung zum Testen von Antikörpern gegen lösliche Antigene | |
IE75725B1 (en) | Ligand gold bonding | |
WO1987002063A1 (en) | Magnetic-polymer particles | |
JPS6262289B2 (de) | ||
JPS6338668B2 (de) | ||
CA2093415C (en) | Test method and reagent kit therefor | |
CA2084492C (en) | Multivalent dextran reagent for use in precipitation tests | |
JPH08198911A (ja) | ビオチン化ラテックス小球、その小球の製造方法および生物学的検出用試薬としての使用 | |
CN112175225A (zh) | 一种聚乙二醇修饰的固相表面及其制备方法和应用 | |
US6262256B1 (en) | Article for tuesyl-activated dextran for solid-phase coupling | |
EP0859793B1 (de) | Die konjugation von liganden an immobilisierte proteine in einem organischen lösungsmittel | |
WO1987004794A1 (en) | Latex agglutination using avidin/biotin system | |
WO1984003358A1 (en) | Insoluble surfaces treated to inhibit non-specific protein binding | |
JP3220545B2 (ja) | リューマチ性因子決定法および該方法実施用試薬 | |
Richter et al. | Fluoro-immuno-cytoadherence (FICA): A new method for the identification and enumeration of antigen-binding cells | |
AU626563B2 (en) | Ion-capture reagents and methods for performing binding assays | |
Sompuram | Purification of immunoglobulins, their bonding onto latex particles and the development of latex agglutination test for mouse immunoglobulin-G for monoclonal antibody assessment |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PUAI | Public reference made under article 153(3) epc to a published international application that has entered the european phase |
Free format text: ORIGINAL CODE: 0009012 |
|
AK | Designated contracting states |
Designated state(s): BE DE FR GB IT NL SE |
|
17P | Request for examination filed |
Effective date: 19850805 |
|
17Q | First examination report despatched |
Effective date: 19880118 |
|
GRAA | (expected) grant |
Free format text: ORIGINAL CODE: 0009210 |
|
AK | Designated contracting states |
Kind code of ref document: B1 Designated state(s): BE DE FR GB IT NL SE |
|
REF | Corresponds to: |
Ref document number: 3479443 Country of ref document: DE Date of ref document: 19890921 |
|
ITF | It: translation for a ep patent filed |
Owner name: BUGNION S.P.A. |
|
ET | Fr: translation filed | ||
PLBI | Opposition filed |
Free format text: ORIGINAL CODE: 0009260 |
|
26 | Opposition filed |
Opponent name: BEHRINGWERKE AKTIENGESELLSCHAFT Effective date: 19900516 |
|
NLR1 | Nl: opposition has been filed with the epo |
Opponent name: BEHRINGWERKE AG |
|
PGFP | Annual fee paid to national office [announced via postgrant information from national office to epo] |
Ref country code: SE Payment date: 19910614 Year of fee payment: 8 Ref country code: GB Payment date: 19910614 Year of fee payment: 8 |
|
PGFP | Annual fee paid to national office [announced via postgrant information from national office to epo] |
Ref country code: FR Payment date: 19910619 Year of fee payment: 8 |
|
ITTA | It: last paid annual fee | ||
PGFP | Annual fee paid to national office [announced via postgrant information from national office to epo] |
Ref country code: NL Payment date: 19910630 Year of fee payment: 8 |
|
PGFP | Annual fee paid to national office [announced via postgrant information from national office to epo] |
Ref country code: DE Payment date: 19910723 Year of fee payment: 8 |
|
RDAG | Patent revoked |
Free format text: ORIGINAL CODE: 0009271 |
|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: PATENT REVOKED |
|
27W | Patent revoked |
Effective date: 19911124 |
|
GBPR | Gb: patent revoked under art. 102 of the ep convention designating the uk as contracting state | ||
NLR2 | Nl: decision of opposition | ||
PGFP | Annual fee paid to national office [announced via postgrant information from national office to epo] |
Ref country code: BE Payment date: 19920903 Year of fee payment: 9 |
|
EUG | Se: european patent has lapsed |
Ref document number: 84304370.4 Effective date: 19920415 |